Use of Sodium Glucose Co-Transporter 2 Inhibitor (SGLT2i) in Geriatric Population

Aim: Diabetes treatment and follow-up is more difficult sensitive in the elderly. Sodium glucose co-transporter type 2 (SGLT2) inhibitors are newly developed antidiabetic agents. In geriatric age group, use of SGLT2 may be riskier terms side effects. We planned to evaluate effect tolerability using patients. Material Methods: Patients over 65 years with a diagnosis DM who were started on empagliflozin or dapagliflozin our center included study. A total 52 patients The study was designed as retrospective file scan. Before after inhibitor treatment, biochemical data, drug-related effects drug withdrawal information recorded. Results: statistically significant decrease observed fasting blood (FBG), postprandial (PPBG), HbA1c values started. While urea creatinine increased eGFR value. After albumin/creatinine ratio spot urine an increase hemoglobin hematocrit observed. No complaints reported 31 (59.6%) no detected. Side associated 21 (40.3%). total, continued 41 (78.8%) out patients, while discontinued 11 (21.2%). Conclusion: population age, glycemic control SGLT successful, rates within acceptable limits.